Dagmar Kubitza

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Therapeutic Drug Monitoring, Pharmacology, Clinical Pharmacology +5

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 426 citations · Full text

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

Corinna Weinz, Thomas Schwarz, Dagmar Kubitza et al. · Drug Metabolism and Disposition · 2009 · 373 citations

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Wolfgang Mueck, Dagmar Kubitza, Michael Becka · British Journal of Clinical Pharmacology · 2013 · 364 citations · Full text